

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS	28	Mar 20	EVENTLINE will be removed from STN
NEWS	29	Mar 24	PATDPAFULL now available on STN
NEWS	30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	31	Apr 11	Display formats in DGENE enhanced
NEWS	32	Apr 14	MEDLINE Reload
NEWS	33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	36	Apr 28	RDISCLOSURE now available on STN
NEWS	37	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information

NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:51:03 ON 05 MAY 2003

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, japio, ceaba, biobusiness, biosis  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 16:51:39 ON 05 MAY 2003

FILE 'USPATFULL' ENTERED AT 16:51:39 ON 05 MAY 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'CEABA-VTB' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'BIOBUSINESS' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOSIS' ENTERED AT 16:51:39 ON 05 MAY 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s insulin  
L1 694538 INSULIN

=> s insulin receptor  
L2 33500 INSULIN RECEPTOR

=> s l1 and agonist  
L3 16865 L1 AND AGONIST

=> s l1 antagonist  
MISSING OPERATOR L1 ANTAGONIST  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s l1 and antagonist  
L4 17810 L1 AND ANTAGONIST

=> s l3 and l4  
L5 6354 L3 AND L4

=> s l5 and l2  
L6 618 L5 AND L2

=> s hyperglycemia  
L7 58483 HYPERGLYCEMIA

=> s l6 and l7  
L8 179 L6 AND L7

=> s IM-140  
L9 7 IM-140

=> s IM 140  
L10 7 IM 140

=> d l10 ti abs ibib tot

L10 ANSWER 1 OF 7 MEDLINE

TI AEV-transformed erythroleukemia cell induced differentiation: expression  
of specific cell membrane antigenic molecules.

AB A simultaneous decay of the expression of Im 140 kDa,  
Im 150 kDa and Im 160 kDa high MW membrane antigens, concomitant with the  
cell proliferation arrest, was observed during erythropoietin induced  
differentiation of ts 34 AEV-transformed erythroid cells cultivated at the  
restrictive temperature. Expression of embryo-immature antigens was  
maintained during induced differentiation of erythroleukemia cells, but  
their MW shifted from 50 to 48 kDa, which corresponds to the MW of  
embryo-immature antigens detected on normal erythroid cells. In the  
absence of erythropoietin at the restrictive temperature, conditions under  
which the ts 34 AEV-transformed erythroid cells fail to differentiate and  
maintain their capacity to proliferate, the expression of high MW antigens  
as well as the expression of embryo-immature antigens remained unaffected.  
Therefore, it is shown that the expression of specific membrane antigens  
is modulated under conditions rendering the erythroleukemia cell  
differentiation process possible.

ACCESSION NUMBER: 87155987 MEDLINE

DOCUMENT NUMBER: 87155987 PubMed ID: 3469940

TITLE: AEV-transformed erythroleukemia cell induced  
differentiation: expression of specific cell membrane  
antigenic molecules.

AUTHOR: Raynaud I; Biquard J M; Chambard P; Fasciotto B; Samarut J;  
Blanchet J P; Krsmanovic V

SOURCE: ARCHIVES OF VIROLOGY, (1987) 93 (3-4) 213-22.  
Journal code: 7506870. ISSN: 0304-8608.

PUB. COUNTRY: Austria

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198704

ENTRY DATE: Entered STN: 19900303

Last Updated on STN: 19970203  
Entered Medline: 19870423

L10 ANSWER 2 OF 7 MEDLINE

TI Expression of differentiation and age-related antigens on chicken erythroleukemia cells transformed by avian erythroblastosis virus (AEV).  
AB Immature circulating chicken red cells express on their surface two antigenic molecules referred to as Im 48 kD and Im 140 kD antigens. The Im 140 kD antigen is not present beyond the erythroblast stage while the expression of Im 48 kD antigenic molecule remains detectable on circulating erythrocytes of embryos and young chickens, but not on erythrocytes of adult animals. In addition to Im 48 kD and Im 140 kD antigens, the avian erythroblastosis virus (AEV)-transformed erythroid cells express two novel high molecular weight (MW) immature antigens referred to as Im 150 kD and Im 160 kD. Since the transformed erythroid cells are apparently blocked at a stage close to the colony-forming units erythrocytic (CFU-E), these molecules might be expressed on these progenitor cells. The age-related antigenic molecules referred to as E1 48 kD and A 40 kD/A 85 kD antigens are detected on erythrocytes of embryos (and young chickens) and adult animals respectively. The E1 48 kD antigen as well as an antigen related to the A 40 kD were also detected on AEV-transformed erythroid cells deriving from both young chicken bone marrow and yolk sac. The presence of an adult antigen on the embryonic cells might well be related to the transformation by AEV, since the yolk sac CFU-E progenitor cells do not bear the adult antigenicity.

ACCESSION NUMBER: 84004779 MEDLINE

DOCUMENT NUMBER: 84004779 PubMed ID: 6578052

TITLE: Expression of differentiation and age-related antigens on chicken erythroleukemia cells transformed by avian erythroblastosis virus (AEV).

AUTHOR: Krsmanovic V; Blanchet J P; Park I; Raynaud I

SOURCE: EXPERIMENTAL CELL RESEARCH, (1983 Sep) 147 (2) 351-8.  
Journal code: 0373226. ISSN: 0014-4827.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198311

ENTRY DATE: Entered STN: 19900319

Last Updated on STN: 19970203

Entered Medline: 19831123

L10 ANSWER 3 OF 7 USPATFULL

TI Substituted 3-phenylpyrazoles

AB Substituted 3-phenylpyrazoles I ##STR1## are used as herbicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:45163 USPATFULL

TITLE: Substituted 3-phenylpyrazoles

INVENTOR(S): von dem Bussche-Hunnefeld, Christoph-Sweder, Mannheim, Germany, Federal Republic of  
Klintz, Ralf, Gruenstadt, Germany, Federal Republic of  
Hamprrecht, Gerhard, Weinheim, Germany, Federal Republic of  
Heistracher, Elisabeth, Ludwigshafen, Germany, Federal Republic of  
Schafer, Peter, Ottersheim, Germany, Federal Republic of  
Ditrich, Klaus, Gonnheim, Germany, Federal Republic of  
Westphalen, Karl-Otto, Speyer, Germany, Federal Republic of  
Gerber, Matthias, Limburgerhof, Germany, Federal Republic of

PATENT ASSIGNEE(S): Walter, Helmut, Obrigheim, Germany, Federal Republic of  
BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal  
Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744426		19980428
	WO 9533728		19951214
APPLICATION INFO.:	US 1996-750231		19961126 (8)
	WO 1995-EP2062		19950531
			19961126 PCT 371 date
			19961126 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4419517	19940603
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Keil & Weinkauff	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4397	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 7 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

TI Expression of differentiation and age-related antigens on chicken erythroleukemia cells transformed by avian erythroblastosis virus (AEV).

AB Immature circulating chicken red cells express on their surface two antigenic molecules referred to as Im 48 kD and Im 140 kD antigens. The Im 140 kD antigen is not present beyond the erythroblast stage while the expression of Im 48 kD antigenic molecule remains detectable on circulating erythrocytes of embryos and young chickens, but not on erythrocytes of adult animals. In addition to Im 48 kD and Im 140 kD antigens, the avian erythroblastosis virus (AEV)-transformed erythroid cells express two novel high molecular weight (MW) immature antigens referred to as Im 150 kD and Im 160 kD. Since the transformed erythroid cells are apparently blocked at a stage close to the colony-forming units erythrocytic (CFU-E), these molecules might be expressed on these progenitor cells. The age-related antigenic molecules referred to as E1 48 kD and A 40 kD/A 85 kD antigens are detected on erythrocytes of embryos (and young chickens) and adult animals respectively. The E1 48 kD antigen as well as an antigen related to the A 40 kD were also detected on AEV-transformed erythroid cells deriving from both young chicken bone marrow and yolk sac. The presence of an adult antigen on the embryonic cells might well be related to the transformation by AEV, since the yolk sac CFU-E progenitor cells do not bear the adult antigenicity.

ACCESSION NUMBER: 83245933 EMBASE

DOCUMENT NUMBER: 1983245933

TITLE: Expression of differentiation and age-related antigens on chicken erythroleukemia cells transformed by avian erythroblastosis virus (AEV).

AUTHOR: Krsmanovic V.; Blanchet J.P.; Park I.; Raynaud I.

CORPORATE SOURCE: Unite Virol., INSERM U51, Groupe Rech. no. 33, 69371 Lyon Cedex, France

SOURCE: Experimental Cell Research, (1983) 147/2 (351-358).  
CODEN: ECREAL

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 016 Cancer  
047 Virology  
026 Immunology, Serology and Transplantation

LANGUAGE: English

L10 ANSWER 5 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI AEV-TRANSFORMED ERYTHROLEUKEMIA CELL INDUCED DIFFERENTIATION EXPRESSION OF SPECIFIC CELL MEMBRANE ANTIGENIC MOLECULES.  
AB A simultaneous decay of the expression of Im 140 kDa, Im 150 kDa and Im 160 kDa high MW membrane antigens, concomitant with the cell proliferation arrest, was observed during erythropoietin induced differentiation of ts34 AEV-transformed erythroid cells cultivated at the restrictive temperature. Expression of embryo-immature antigens was maintained during induced differentiation of erythroleukemia cells, but their MW shifted from 50 to 48 kDa, which corresponds to the MW of embryo-immature antigens detected on normal erythroid cells. In the absence of erythropoietin at the restrictive temperature, conditions under which the ts34 AEV-transformed erythroid cells fail to differentiate and maintain their capacity to proliferate, the expression of high MW antigens as well as the expression of embryo-immature antigens remained unaffected. Therefore, it is shown that the expression of specific membrane antigens is modulated under conditions rendering the erythroleukemia cell differentiation process possible.

ACCESSION NUMBER: 1987:253120 BIOSIS

DOCUMENT NUMBER: BA84:6092

TITLE: AEV-TRANSFORMED ERYTHROLEUKEMIA CELL INDUCED DIFFERENTIATION EXPRESSION OF SPECIFIC CELL MEMBRANE ANTIGENIC MOLECULES.

AUTHOR(S): RAYNAUD I; BIQUARD J M; CHAMBARD P; FASCIOTTO B; SAMARUT J; BLANCHET J P; KRSMANOVIC V

CORPORATE SOURCE: UNITE VIROL. INSERM U 51, CNRS, 1 PL. PR. J. RENAUT, 69371 LYON CEDEX 09, FR.

SOURCE: ARCH VIROL, (1987) 93 (3-4), 213-222.

CODEN: ARVIDF. ISSN: 0304-8608.

FILE SEGMENT: BA; OLD

LANGUAGE: English

L10 ANSWER 6 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI EXPRESSION OF DIFFERENTIATION AND AGE RELATED ANTIGENS ON CHICKEN ERYTHRO LEUKEMIA CELLS TRANSFORMED BY AVIAN ERYTHROBLASTOSIS VIRUS.  
AB Immature circulating chicken red blood cells express on their surface 2 antigenic molecules referred to as Im 48 kD [kilodalton] and Im 140 kD antigens. The Im 140 kD antigen is not present beyond the erythroblast stage while the expression of Im 48 kD antigenic molecule remains detectable on circulating erythrocytes of embryos and young chickens, but not on erythrocytes of adult animals. In addition to Im 48 kD and Im 48 kD antigens, the avian erythroblastosis virus (AEV)-transformed erythroid cells express 2 novel high MW immature antigens referred to as Im 150 kD and Im 160 kD. Since the transformed erythroid cells are apparently blocked at a stage close to the colony-forming units erythrocytic (CFU-E), these molecules might be expressed on these progenitor cells. The age-related antigen molecules referred to as E1 48 kD and A 40 kD/A 85 kD antigens are detected on erythrocytes of embryos (and young chickens) and adult animals, respectively. The E1 48 kD antigen as well as an antigen related to the A 40 kD were also detected on AEV-transformed erythroid cells deriving from both young chicken bone marrow and yolk sac. The presence of an adult antigen on the embryonic cells might well be related to the transformation by AEV, since the yolk sac CFU-E progenitor cells do not bear the adult antigenicity.

ACCESSION NUMBER: 1984:243685 BIOSIS

DOCUMENT NUMBER: BA77:76669

TITLE: EXPRESSION OF DIFFERENTIATION AND AGE RELATED ANTIGENS ON CHICKEN ERYTHRO LEUKEMIA CELLS TRANSFORMED BY AVIAN ERYTHROBLASTOSIS VIRUS.

AUTHOR(S): KRSMANOVIC V; BLANCHET J P; PARK I; RAYNAUD I

CORPORATE SOURCE: UNITE DE VIROLOGIE, INSERM U51, GROUPE DE RECHERCHE NO. 33, 69371 LYON CEDEX, FRANCE.

SOURCE: EXP CELL RES, (1983) 147 (2), 351-358.  
CODEN: ECREAL. ISSN: 0014-4827.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English

L10 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI IDENTIFICATION OF 2 TYPES OF IMMATURE ANTIGENIC MOLECULES ON CHICKEN RED CELLS.  
AB Surface-labeled antigen analysis of circulating embryonic erythrocytes shows that the population of 48,000 D [dalton] antigenic molecules involves an age-related antigenic complex referred to as E1 48 K component and an antigenic molecule expressed on immature red cells from anemic adult chickens referred to as IM 48 K component. A second immature antigenic molecular species of 140,000 D was detected on red cells from anemic birds and is referred to as Im 140 K component. The Im 48 K and Im 140 K components have no common determinants, although they are both found on immature red cells of anemic animals. These 2 immature antigens could be involved in the differentiation process, possibly at different levels of erythroid progenitors.

ACCESSION NUMBER: 1983:268858 BIOSIS  
DOCUMENT NUMBER: BA76:26350  
TITLE: IDENTIFICATION OF 2 TYPES OF IMMATURE ANTIGENIC MOLECULES ON CHICKEN RED CELLS.  
AUTHOR(S): KRSMANOVIC V; PERISIC O; BLANCHET J P; LEE S Y; GREENLAND T  
CORPORATE SOURCE: UNITE VIROLOGIE, INSERM U51, GROUPE RECHERCHE N 33, 69371 LYON CEDEX 2.  
SOURCE: EXP CELL RES, (1982) 140 (2), 434-440.  
CODEN: ECREAL. ISSN: 0014-4827.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 16:51:03 ON 05 MAY 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, JAPIO, CEABA-VTB, BIOBUSINESS, BIOSIS' ENTERED AT 16:51:39 ON 05 MAY 2003

L1 694538 S INSULIN  
L2 33500 S INSULIN RECEPTOR  
L3 16865 S L1 AND AGONIST  
L4 17810 S L1 AND ANTAGONIST  
L5 6354 S L3 AND L4  
L6 618 S L5 AND L2  
L7 58483 S HYPERGLYCEMIA  
L8 179 S L6 AND L7  
L9 7 S IM-140  
L10 7 S IM 140

=> s l10 not l9

L11 0 L10 NOT L9

=> s IM 175

L12 3 IM 175

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 3 USPATFULL  
TI Method for induction of differentiation of osteoclasts  
AB The present invention provides a simple method of producing osteoclasts from monocytes, a agent comprising monoclonal antibody to be used for the method, and a method for screening a ligand that induces differentiation of monocytes to osteoclasts. Differentiation of

monocytes to osteoclasts can be induced in vitro by culturing isolated human peripheral blood monocytes in the presence of monoclonal antibody that binds to a portion of FRP-1 protein exposed on the surface of monocytes. Such a differentiation system can be utilized to isolate a ligand that binds to FRP-1 protein and induces differentiation of monocytes to osteoclasts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:54355 USPATFULL  
TITLE: Method for induction of differentiation of osteoclasts  
INVENTOR(S): Ito, Yasuhiko, Mie, JAPAN  
Higuchi, Shigeomi, Mie, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002031514	A1	20020314
APPLICATION INFO.:	US 2001-993076	A1	20011106 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-99174, filed on 18 Jun 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-14788	19980108
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 176 FEDERAL STREET, BOSTON, MA, 02110-2214	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	454	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 3 USPATFULL

TI Substituted 3-phenylpyrazoles

AB Substituted 3-phenylpyrazoles I ##STR1## are used as herbicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:45163 USPATFULL  
TITLE: Substituted 3-phenylpyrazoles  
INVENTOR(S): von dem Bussche-Hunnefeld, Christoph-Sweder, Mannheim, Germany, Federal Republic of  
Klintz, Ralf, Gruenstadt, Germany, Federal Republic of  
Hamprrecht, Gerhard, Weinheim, Germany, Federal Republic of  
Heistracher, Elisabeth, Ludwigshafen, Germany, Federal Republic of  
Schafer, Peter, Ottersheim, Germany, Federal Republic of  
Ditrich, Klaus, Gonnheim, Germany, Federal Republic of  
Westphalen, Karl-Otto, Speyer, Germany, Federal Republic of  
Gerber, Matthias, Limburgerhof, Germany, Federal Republic of  
Walter, Helmut, Obrigheim, Germany, Federal Republic of  
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744426		19980428
	WO 9533728		19951214
APPLICATION INFO.:	US 1996-750231		19961126 (8)
	WO 1995-EP2062		19950531



19961126 PCT 371 date  
19961126 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4419517	19940603
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Keil & Weinkauff	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4397	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 3 USPATFULL

TI Fungicidal .alpha.-(alkynylphenyl)azole ethanol compounds  
AB The invention provides novel .alpha.-(ethynyl substituted phenyl)-.alpha.-hydrocarbyl-1H-azole-ethanols wherein the azole group is 1,2,4-triazol-1-yl or imidazol-1-yl, the ethynyl group is unsubstituted or substituted and the phenyl group may bear an additional substituent and ethers thereof, which are useful as fungicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 86:49553 USPATFULL  
TITLE: Fungicidal .alpha.-(alkynylphenyl)azole ethanol compounds  
INVENTOR(S): Schaub, Fritz, Aesch, Switzerland  
Schneider, Rupert, Riehen, Switzerland  
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4609668		19860902
APPLICATION INFO.:	US 1984-644401		19840824 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1983-23412	19830901
	GB 1984-8655	19840404
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rollins, Alton D.	
LEGAL REPRESENTATIVE:	Dolezalova, Hana, Larson, Jacqueline S.	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1,13	
LINE COUNT:	630	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:51:03 ON 05 MAY 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, JAPIO, CEABA-VTB, BIOBUSINESS, BIOSIS' ENTERED AT 16:51:39 ON 05 MAY 2003

L1 694538 S INSULIN  
L2 33500 S INSULIN RECEPTOR  
L3 16865 S L1 AND AGONIST  
L4 17810 S L1 AND ANTAGONIST  
L5 6354 S L3 AND L4  
L6 618 S L5 AND L2  
L7 58483 S HYPERGLYCEMIA  
L8 179 S L6 AND L7

L9 7 S IM-140  
L10 7 S IM 140  
L11 0 S L10 NOT L9  
L12 3 S IM 175

=> s l8 and IM 103  
L13 0 L8 AND IM 103

=> s IM 103  
L14 7 IM 103

=> s l8 and l9  
L15 0 L8 AND L9

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 3 USPATFULL

TI Method for induction of differentiation of osteoclasts  
AB The present invention provides a simple method of producing osteoclasts from monocytes, a agent comprising monoclonal antibody to be used for the method, and a method for screening a ligand that induces differentiation of monocytes to osteoclasts. Differentiation of monocytes to osteoclasts can be induced in vitro by culturing isolated human peripheral blood monocytes in the presence of monoclonal antibody that binds to a portion of FRP-1 protein exposed on the surface of monocytes. Such a differentiation system can be utilized to isolate a ligand that binds to FRP-1 protein and induces differentiation of monocytes to osteoclasts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:54355 USPATFULL  
TITLE: Method for induction of differentiation of osteoclasts  
INVENTOR(S): Ito, Yasuhiko, Mie, JAPAN  
Higuchi, Shigeomi, Mie, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002031514	A1	20020314
APPLICATION INFO.:	US 2001-993076	A1	20011106 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-99174, filed on 18 Jun 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-14788	19980108
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 176 FEDERAL STREET, BOSTON, MA, 02110-2214	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	454	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 3 USPATFULL

TI Substituted 3-phenylpyrazoles  
AB Substituted 3-phenylpyrazoles I ##STR1## are used as herbicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:45163 USPATFULL  
TITLE: Substituted 3-phenylpyrazoles  
INVENTOR(S): von dem Bussche-Hunnefeld, Christoph-Sweder, Mannheim, Germany, Federal Republic of

on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-161453P	19991025 (60)
	US 2001-272624P	20010301 (60)
	US 2001-323016P	20010911 (60)
	US 2001-340045P	20011130 (60)
	US 2001-328738P	20011011 (60)
	US 2001-338015P	20011108 (60)
	US 2001-343523P	20011220 (60)
	US 1999-126056P	19991019 (60)
	US 1999-124087P	19990311 (60)
	US 1998-109923P	19981124 (60)
	US 1998-109924P	19981124 (60)
	US 1998-110127P	19981127 (60)
	US 1998-112206P	19981215 (60)
	US 1999-145823P	19990727 (60)
	US 1999-137745P	19990603 (60)
	US 1999-140028P	19990616 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
LINE COUNT:	19428	

L8 ANSWER 4 OF 179 USPATFULL

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2003:120277 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082758	A1	20030501
APPLICATION INFO.:	US 2002-103313	A1	20020322 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764854, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)

US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)

US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 29207

L8 ANSWER 5 OF 179 USPATFULL

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2003:120200 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082681	A1	20030501
APPLICATION INFO.:	US 2002-91391	A1	20020307 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764903, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)

US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)

US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)



US 2000-209467P 20000607 (60)  
US 2000-205515P 20000519 (60)  
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 21414

L8 ANSWER 6 OF 179 USPATFULL

TI TUMOR NECROSIS FACTOR RECEPTOR RELATED GENE 12 POLYPEPTIDES

AB The present invention relates to a novel human protein called TNFR  
Related Gene 12, and isolated polynucleotides encoding this protein.  
Also provided are vectors, host cells, antibodies, and recombinant  
methods for producing this human protein. The invention further relates  
to diagnostic and therapeutic methods useful for diagnosing and treating  
disorders related to this novel human protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:120049 USPATFULL  
TITLE: TUMOR NECROSIS FACTOR RECEPTOR RELATED GENE 12  
POLYPEPTIDES  
INVENTOR(S): NI, JIAN, ROCKVILLE, MD, UNITED STATES  
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082532	A1	20030501
APPLICATION INFO.:	US 1999-421112	A1	19991019 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104950P	19981020 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	8879	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 179 USPATFULL

TI 47 human secreted proteins

AB The present invention relates to novel human secreted proteins and  
isolated nucleic acids containing the coding regions of the genes  
encoding such proteins. Also provided are vectors, host cells,  
antibodies, and recombinant methods for producing human secreted  
proteins. The invention further relates to diagnostic and therapeutic  
methods useful for diagnosing and treating diseases, disorders, and/or  
conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2003:113664 USPATFULL  
TITLE: 47 human secreted proteins  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Endress, Gregory A., Silver Spring, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Ni, Jian, Rockville, MD, UNITED STATES  
Duan, Roxanne D., Bethesda, MD, UNITED STATES

Moore, Paul A., Germantown, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Florence, Kimberly A., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078405	A1	20030424
APPLICATION INFO.:	US 2001-895298	A1	20010702 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-591316, filed on 9 Jun 2000, PENDING Continuation-in-part of Ser. No. WO 1999-US29950, filed on 16 Dec 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113006P	19981218 (60)
	US 1998-112809P	19981217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18444	

L8 ANSWER 8 OF 179 USPATFULL  
TI 97 human secreted proteins  
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

ACCESSION NUMBER: 2003:113076 USPATFULL  
TITLE: 97 human secreted proteins  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Florence, Kimberly, Rockville, MD, UNITED STATES  
Ni, Jian, Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Olsen, Henrik, Gaithersburg, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Young, Paul, Gaithersburg, MD, UNITED STATES  
Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
Soppet, Daniel R., Centreville, CA, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Endress, Gregory A., Potomac, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003077809	A1	20030424
APPLICATION INFO.:	US 2001-892877	A1	20010628 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-437658, filed on 10 Nov 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US9847, filed on 6 May 1999, UNKNOWN		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1998-85093P 19980512 (60)  
 US 1998-85094P 19980512 (60)  
 US 1998-85105P 19980512 (60)  
 US 1998-85180P 19980512 (60)  
 US 1998-85927P 19980518 (60)  
 US 1998-85906P 19980518 (60)  
 US 1998-85920P 19980518 (60)  
 US 1998-85924P 19980518 (60)  
 US 1998-85922P 19980518 (60)  
 US 1998-85923P 19980518 (60)  
 US 1998-85921P 19980518 (60)  
 US 1998-85925P 19980518 (60)  
 US 1998-85928P 19980518 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 25009

L8 ANSWER 9 OF 179 USPATFULL

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "reproductive system related antigens," and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113075 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003077808	A1	20030424
APPLICATION INFO.:	US 2001-764891	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)

US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)

US 2000-205515P 20000519 (60)  
 US 2001-259678P 20010105 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 59131  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 179 USPATFULL

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2003:112971 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003077704	A1	20030424
APPLICATION INFO.:	US 2002-74095	A1	20020214 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764860, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)

US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)

US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

FILE SEGMENT:

LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS:

Utility

APPLICATION

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

24



EXEMPLARY CLAIM: 1  
LINE COUNT: 21987

Klintz, Ralf, Gruenstadt, Germany, Federal Republic of  
 Hamprecht, Gerhard, Weinheim, Germany, Federal Republic  
 of  
 Heistracher, Elisabeth, Ludwigshafen, Germany, Federal  
 Republic of  
 Schafer, Peter, Ottersheim, Germany, Federal Republic  
 of  
 Ditrich, Klaus, Gonnheim, Germany, Federal Republic of  
 Westphalen, Karl-Otto, Speyer, Germany, Federal  
 Republic of  
 Gerber, Matthias, Limburgerhof, Germany, Federal  
 Republic of  
 Walter, Helmut, Obrigheim, Germany, Federal Republic of  
 BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal  
 Republic of (non-U.S. corporation)

PATENT ASSIGNEE(S) :

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744426		19980428
	WO 9533728		19951214
APPLICATION INFO.:	US 1996-750231		19961126 (8)
	WO 1995-EP2062		19950531
			19961126 PCT 371 date
			19961126 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4419517	19940603
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Keil & Weinkauff	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4397	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 3 OF 3 USPATFULL

TI Fungicidal .alpha.-(alkynylphenyl)azole ethanol compounds  
 AB The invention provides novel .alpha.-(ethynyl substituted  
 phenyl)-.alpha.-hydrocarbyl-1H-azole-ethanols wherein the azole group is  
 1,2,4-triazol-1-yl or imidazol-1-yl, the ethynyl group is unsubstituted  
 or substituted and the phenyl group may bear an additional substituent  
 and ethers thereof, which are useful as fungicides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 86:49553 USPATFULL  
 TITLE: Fungicidal .alpha.-(alkynylphenyl)azole ethanol  
 compounds  
 INVENTOR(S): Schaub, Fritz, Aesch, Switzerland  
 Schneider, Rupert, Riehen, Switzerland  
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4609668		19860902
APPLICATION INFO.:	US 1984-644401		19840824 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1983-23412	19830901
	GB 1984-8655	19840404
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Rollins, Alton D.  
LEGAL REPRESENTATIVE: Dolezalova, Hana, Larson, Jacqueline S.  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1,13  
LINE COUNT: 630  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s nonpeptidyl compound  
L16 0 NONPEPTIDYL COMPOUND

=> s nonpeptidyl compound  
L17 7 NONPEPTIDYL COMPOUND

=> d his

(FILE 'HOME' ENTERED AT 16:51:03 ON 05 MAY 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, JAPIO, CEABA-VTB, BIOBUSINESS, BIOSIS' ENTERED AT 16:51:39 ON 05 MAY 2003

L1 694538 S INSULIN  
L2 33500 S INSULIN RECEPTOR  
L3 16865 S L1 AND AGONIST  
L4 17810 S L1 AND ANTAGONIST  
L5 6354 S L3 AND L4  
L6 618 S L5 AND L2  
L7 58483 S HYPERGLYCEMIA  
L8 179 S L6 AND L7  
L9 7 S IM-140  
L10 7 S IM 140  
L11 0 S L10 NOT L9  
L12 3 S IM 175  
L13 0 S L8 AND IM 103  
L14 7 S IM 103  
L15 0 S L8 AND L9  
L16 0 S NONPEPTIDYL COMPOUND  
L17 7 S NONPEPTIDYL COMPOUND

=> s l8 and l17  
L18 0 L8 AND L17

=> d l17 ti abs ibib tot

L17 ANSWER 1 OF 7 USPATFULL  
TI Treatment of aldehyde-fixed tissue  
AB A method of preparing a biological tissue for implantation that has been treated with an aldehyde, the method utilizing a cyclic nonpeptidyl amide-functional and/or imide-functional compound to remove excess aldehyde from the treated biological material, thereby detoxifying the biological tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:75330 USPATFULL  
TITLE: Treatment of aldehyde-fixed tissue  
INVENTOR(S): Trescony, Paul V., Champlin, MN, United States  
Zilla, Peter, Cape Town, South Africa  
PATENT ASSIGNEE(S): Medtronic, Inc., Minneapolis, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919472		19990706
APPLICATION INFO.:	US 1996-619843		19960319 (8)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: Granted  
PRIMARY EXAMINER: Dees, Jose' G.  
ASSISTANT EXAMINER: Shelborne, Kathryn E.  
LEGAL REPRESENTATIVE: Patton, Harold R., Forrest, Peter  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
LINE COUNT: 514  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 7 USPATFULL

TI Ras farnesyl transferase inhibitors  
AB Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase as indicated.  
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:150943 USPATFULL  
TITLE: Ras farnesyl transferase inhibitors  
INVENTOR(S): Marsters, Jr., James C., Oakland, CA, United States  
Brown, Michael S., Dallas, TX, United States  
Crowley, Craig W., Portola Valley, CA, United States  
Goldstein, Joseph L., Dallas, TX, United States  
James, Guy L., Dallas, TX, United States  
McDowell, Robert S., San Francisco, CA, United States  
Oare, David, Belmont, CA, United States  
Rawson, Thomas E., Mountain View, CA, United States  
Reynolds, Mark, South San Francisco, CA, United States  
Somers, Todd C., Foster City, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)  
Board of Regents University of Texas, Austin, TX,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843941		19981201
	WO 9426723		19941124
APPLICATION INFO.:	US 1994-313068		19940926 (8)
	WO 1994-US5157		19940510
			19940926 PCT 371 date
			19940926 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-82202, filed on 24 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61961, filed on 14 May 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bond, Robert T.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1,15		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	8094		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 7 USPATFULL

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a  
AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potentially inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided

in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:91522 USPATFULL  
TITLE: Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a  
INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States  
Barker, Peter, El Granada, CA, United States  
Gadek, Thomas, Oakland, CA, United States  
McDowell, Robert, San Francisco, CA, United States  
McGee, Lawrence, Pacifica, CA, United States  
Somers, Todd, Montara, CA, United States  
Webb, Rob, Moss Beach, CA, United States  
Robarge, Kirk, San Francisco, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674865		19971007
APPLICATION INFO.:	US 1995-451794		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Wong, King Lit		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	13454		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 7 USPATFULL

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor  
AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potentially inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:91520 USPATFULL  
TITLE: Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor  
INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States  
Barker, Peter, El Granada, CA, United States  
Gadek, Thomas, Oakland, CA, United States  
McDowell, Robert, San Francisco, CA, United States  
McGee, Lawrence, Pacifica, CA, United States  
Somers, Todd, Montara, CA, United States  
Webb, Rob, Moss Beach, CA, United States  
Robarge, Kirk, San Francisco, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674863		19971007
APPLICATION INFO.:	US 1995-451849		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Wong, King Lit		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	13521		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 7 USPATFULL

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor

AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:78435 USPATFULL

TITLE: Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor

INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States  
Barker, Peter, El Granada, CA, United States  
Gadek, Thomas, Oakland, CA, United States  
McDowell, Robert, San Francisco, CA, United States  
McGee, Lawrence, Pacifica, CA, United States  
Somers, Todd, Montara, CA, United States  
Webb, Rob, Moss Beach, CA, United States  
Robarge, Kirk, San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5663166		19970902
APPLICATION INFO.:	US 1995-452056		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bond, Robert T.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	13432		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 7 USPATFULL

TI Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b  
III.sub.a receptor  
AB A benzodiazepinedione derivative which acts as a nonpeptidyl platelet  
aggregation inhibitor is provided. This inhibitor potentially inhibits  
fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided  
in therapeutic compositions for the treatment of diseases for which  
blocking platelet aggregation is indicated. These nonpeptidyl inhibitors  
are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:94579 USPATFULL

TITLE: Nonpeptidyl integrin inhibitors having specificity for  
the GPII.sub.b III.sub.a receptor

INVENTOR(S): Blackburn, Brent, San Francisco, CA, United States  
Barker, Peter, El Granada, CA, United States  
Gadek, Thomas, Oakland, CA, United States  
McDowell, Robert, San Francisco, CA, United States  
McGee, Lawrence, Pacifica, CA, United States  
Somers, Todd, Montara, CA, United States  
Webb, Rob, Moss Beach, CA, United States  
Robarge, Kirk, San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5565449		19961015
APPLICATION INFO.:	US 1995-452479		19950526 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-70457, filed on 8 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 1991-781477, filed on 18 Oct 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bond, Robert T.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1,2		
LINE COUNT:	13455		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 7 USPATFULL

TI Ras farnesyl transferase inhibitors  
AB Benzodiazepine derivatives are disclosed that act as potent inhibitors  
of ras farnesyl:protein transferase. Pharmaceutical compositions  
containing these benzodiazepines are provided for treatment of diseases  
for which inhibition of the ras farnesyl:protein transferase is  
indicated. Also disclosed are benzazepines of the following general  
formula (II) having similar utility as the aforementioned  
benzodiazepines: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:58332 USPATFULL

TITLE: Ras farnesyl transferase inhibitors

INVENTOR(S): Marsters, Jr., James C., Oakland, CA, United States  
Brown, Michael S., Dallas, TX, United States  
Crowley, Craig W., Portola Valley, CA, United States  
Goldstein, Joseph L., Dallas, TX, United States  
James, Guy L., Dallas, TX, United States  
McDowell, Robert S., San Francisco, CA, United States  
Oare, David, Belmont, CA, United States  
Rawson, Thomas E., Mountain View, CA, United States

PATENT ASSIGNEE(S): Reynolds, Mark, So. San Francisco, CA, United States  
 Somers, Todd C., Montara, CA, United States  
 Genentech, Inc., South San Francisco, CA, United States  
 (U.S. corporation)  
 Board of Regents, The University of Texas System,  
 Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5532359		19960702
APPLICATION INFO.:	US 1994-328595		19941025 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-82202, filed on 24 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-61961, filed on 14 May 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Datlow, Philip I.		
LEGAL REPRESENTATIVE:	Winter, Daryl B.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	4800		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

=> s his  
 L19 562926 HIS

=> d his

(FILE 'HOME' ENTERED AT 16:51:03 ON 05 MAY 2003)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, JAPIO, CEABA-VTB, BIOBUSINESS, BIOSIS' ENTERED AT 16:51:39 ON 05 MAY 2003

L1 694538 S INSULIN  
 L2 33500 S INSULIN RECEPTOR  
 L3 16865 S L1 AND AGONIST  
 L4 17810 S L1 AND ANTAGONIST  
 L5 6354 S L3 AND L4  
 L6 618 S L5 AND L2  
 L7 58483 S HYPERGLYCEMIA  
 L8 179 S L6 AND L7  
 L9 7 S IM-140  
 L10 7 S IM 140  
 L11 0 S L10 NOT L9  
 L12 3 S IM 175  
 L13 0 S L8 AND IM 103  
 L14 7 S IM 103  
 L15 0 S L8 AND L9  
 L16 0 S NONPEPTIDYL COMPOUND  
 L17 7 S NONPEPTIDYL COMPOUND  
 L18 0 S L8 AND L17  
 L19 562926 S HIS

=> d l8 ti abs ibib 1-10

L8 ANSWER 1 OF 179 MEDLINE  
 TI Desensitization of the insulin receptor by antireceptor antibodies in vivo is blocked by treatment of mice with beta-adrenergic agonists.  
 AB In previous studies we reported that immunization of mice with ungulate insulins induced the development of antiinsulin antibodies, which include an idotype that appeared to recognize the part of the insulin



molecule recognized by the hormone receptor. The antiinsulin antibodies of this idiotypic were replaced spontaneously by antiidiotypic antibodies. The antiidiotypic antibodies, which persisted for about 14 d, mimicked **insulin** and functioned as antibodies to the **insulin receptor**. They induced down regulation, desensitization and refractoriness of the **insulin receptor** and disturbances in glucose homeostasis in vivo (Shechter, Y., D. Elias, R. Maron, and I.R. Cohen., 1984; Elias, D., R. Maron, I.R. Cohen, and Y. Shechter. 1984, J. Biol. Chem. 259: 6411-6419). We now report that effects of the antiidiotypic antibodies on the **insulin receptor** effector system can be modified pharmacologically. Administration of the beta-adrenergic **agonist** isoproterenol during the period of **insulin** resistance (days 26-40 after primary immunization), largely restored fat cell responsiveness to **insulin**, and eliminated the appearance of fasting **hyperglycemia**. This restoration appeared to be caused by inhibition of both **insulin receptor** desensitization and refractoriness. In contrast, down regulation of **insulin** receptors was not reversed by isoproterenol treatment in vivo. The effects of treatment with isoproterenol persisted for 2-4 d after termination of treatment. The beta-**antagonist**, propranolol and more so, the beta 1a-**antagonist** metoprolol, specifically blocked the effect of isoproterenol at a molar ratio of 3-10:1. Oral administration of the cAMP phosphodiesterase inhibitor, aminophylline, was also effective in inhibiting the development of desensitization in fat cells. These results indicate that treatment with beta 1-adrenergic agonists in vivo, or other agents that elevate cellular cAMP levels, can inhibit the development of the "postbinding" defects induced by **insulin-mimicking**, antireceptor antibodies. These observations have both basic and clinical implications.

ACCESSION NUMBER: 88257470 MEDLINE  
DOCUMENT NUMBER: 88257470 PubMed ID: 3290258  
TITLE: Desensitization of the **insulin receptor** by antireceptor antibodies in vivo is blocked by treatment of mice with beta-adrenergic agonists.  
AUTHOR: Elias D; Rapoport M; Cohen I R; Shechter Y  
CORPORATE SOURCE: Department of Hormone Research, Weizmann Institute of Science, Rehovot, Israel.  
SOURCE: JOURNAL OF CLINICAL INVESTIGATION, (1988 Jun) 81 (6) 1979-85.  
Journal code: 7802877. ISSN: 0021-9738.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 198808  
ENTRY DATE: Entered STN: 19900308  
Last Updated on STN: 20000303  
Entered Medline: 19880803

L8 ANSWER 2 OF 179 USPATFULL

TI 25 human prostate and prostate cancer associated proteins  
AB This invention relates to newly identified prostate or prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "prostate antigens" or alternatively "prostate cancer antigens", and the use of such prostate or prostate cancer antigens for detecting disorders of the prostate, particularly the presence of prostate cancer and prostate cancer metastases. This invention relates to prostate or prostate cancer antigens as well as vectors, host cells, antibodies directed to prostate or prostate cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders of the prostate, particularly prostate cancer, and therapeutic methods for

treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of prostate or prostate cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2003:120997 USPATFULL  
TITLE: 25 human prostate and prostate cancer associated proteins  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083481	A1	20030501
APPLICATION INFO.:	US 2002-36542	A1	20020107 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US19666, filed on 20 Jul 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-144972P	19990721 (60)
	US 1999-148681P	19990813 (60)
	US 1999-149173P	19990817 (60)
	US 1999-158004P	19991006 (60)
	US 2000-194689P	20000405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	26241	

L8 ANSWER 3 OF 179 USPATFULL  
TI Blood cell deficiency treatment method  
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

ACCESSION NUMBER: 2003:120747 USPATFULL  
TITLE: Blood cell deficiency treatment method  
INVENTOR(S): Ahlem, Clarence N., San Diego, CA, UNITED STATES  
Reading, Christopher, San Diego, CA, UNITED STATES  
Frincke, James, San Diego, CA, UNITED STATES  
Stickney, Dwight, Granite Bay, CA, UNITED STATES  
Lardy, Henry A., Madison, WI, UNITED STATES  
Marwah, Padma, Middleton, WI, UNITED STATES  
Marwah, Ashok, Middleton, WI, UNITED STATES  
Prendergast, Patrick T., Straffan, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083231	A1	20030501
APPLICATION INFO.:	US 2002-87929	A1	20020301 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-675470, filed		